Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
Other Sizes |
|
Purity: ≥98%
Esmolol HCl (Brevibloc; ASL-8052; ASL 8052), the hydrochloride salt of esmolol, is a potent and cardioselective beta-blocker used to control rapid heartbeats or abnormal heart rhythms. Esmolol is an enantiomeric pair with one asymmetric center; the (+)-enantiomer is inactive and the (-)-enantiomer is active. This is similar to other P-blockers that have an oxypropranolamine nucleus. Esmolol exhibits a swift onset and offset of action, with its primary site of action being on the conduction systems of the sinus node and atrioventricular (AV) node.
Targets |
Adrenergic receptor
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C16H26CLNO4
|
|
---|---|---|
Molecular Weight |
331.83
|
|
Exact Mass |
331.16
|
|
Elemental Analysis |
C, 57.91; H, 7.90; Cl, 10.68; N, 4.22; O, 19.29
|
|
CAS # |
81161-17-3
|
|
Related CAS # |
Esmolol-d7 hydrochloride; 1346598-13-7
|
|
Appearance |
Solid powder
|
|
SMILES |
CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O.Cl
|
|
InChi Key |
GEKNCWBANDDJJL-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C16H25NO4.ClH/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3;/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3;1H
|
|
Chemical Name |
methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate;hydrochloride
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (8.29 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.75 mg/mL (8.29 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.75 mg/mL (8.29 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (301.36 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.0136 mL | 15.0680 mL | 30.1359 mL | |
5 mM | 0.6027 mL | 3.0136 mL | 6.0272 mL | |
10 mM | 0.3014 mL | 1.5068 mL | 3.0136 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02120404 | Active Recruiting |
Drug: Esmolol administration | Septic Shock | Assistance Publique - Hôpitaux de Paris |
April 2015 | Phase 2 |
NCT05567822 | Recruiting | Drug: Esmolol Hydrochloride Drug: normal saline |
Pain, Acute Esmolol |
Aretaieion University Hospital | October 1, 2022 | Not Applicable |
NCT05703048 | Recruiting | Drug: Esmolol Esterase Drug: Dexmedetomidine |
Patient's Satisfaction Depth of Anesthesia |
Tanta University | December 30, 2022 | Not Applicable |
NCT05769868 | Recruiting | Drug: Esmolol Injection [Brevibloc] |
Cirrhosis Diabetes Mellitus Oncologic Disorders |
Consorcio Centro de Investigación Biomédica en Red (CIBER) |
April 18, 2023 | Phase 3 |
NCT05694585 | Not yet recruiting | Drug: Esmolol Drug: saline |
Esmolol Stress Reaction |
Xiumei Song | February 1, 2023 | Phase 4 |